Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

NCT02201992 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT02201992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02201992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 23, 2015
Completion date
May 1, 2036
Enrollment
166 (actual)
Sites
1,618

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene rearrangement, alk gene translocation, alk positive, stage ib non-small cell lung carcinoma ajcc v7, stage ii non-small cell lung cancer ajcc v7, stage iia non-small cell lung carcinoma ajcc v7, stage iib non-small cell lung carcinoma ajcc v7, stage iiia non-small cell lung cancer ajcc v7